Have questions? Call for answers.
ACTIMMUNE®: An immunomodulatory therapy which helps reduce the frequency and severity of serious infections* in patients with chronic granulomatous disease (CGD).
ACTIMMUNE® is an immunomodulatory therapy which helps reduce the frequency and severity of serious infections* in patients with chronic granulomatous disease (CGD).1,2
reduction in the total number and rate of serious infections, including recurrent infections (P < .0001)1,2
reduction in relative risk of serious infections for patients receiving ACTIMMUNE® (P = .0006)1,2
fewer inpatient hospitalization days (P = .02)1,2
As part of a combination treatment regimen along with prophylaxis therapy that includes antibiotics and antifungals, ACTIMMUNE® is recommended by the3-5:
*Serious infection is defined as a clinical event requiring both hospitalization and intravenous antibiotics.
References: 1. ACTIMMUNE® (Interferon gamma-1b) [prescribing information] Horizon. 2. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324(8):509-516. 3. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.e1-e78. 4. Leiding JW, Malech HL, Holland SM. Chronic granulomatous disease. Clinical Focus on Primary Immunodeficiencies. 2013;15:1-9. 5. Mendelian susceptibility to mycobacterial disease. In: Buckley RH, ed. Immune Deficiency Foundation Diagnostic & Clinical Care Guidelines for Primary Immunodeficiency Diseases. 3rd ed. Immune Deficiency Foundation; 2015:25.
ACTIMMUNE® (Interferon gamma-1b) is indicated:
ACTIMMUNE® (Interferon gamma-1b) is indicated: